HIF-1α/PFKFB3信号通路介导GK调节2型糖尿病胰岛β细胞功能的研究进展OACSTPCD
HIF-1α/PFKFB3 Signaling Pathway Mediates GK Regulation of Islets in Type 2 Diabetes β Progress in Cellular Function Research
胰岛β细胞是人体唯一合成并分泌胰岛素的细胞,对血糖稳态的调节至关重要.无氧糖酵解压力持续增加引发胰岛β细胞失代偿是导致2型糖尿病(T2DM)患者胰岛素分泌缺陷或胰岛素抵抗的重要原因之一.葡萄糖激酶(GK)作为葡萄糖传输的主要限速步骤,与胰岛素分泌密切相关.缺氧诱导因子1α亚基(HIF-1α)和6-磷酸果糖-2-激酶(PFKFB3)是糖酵解的关键调节因子,HIF-1α/PFKFB3信号通路参与调节胰岛β细胞复杂的病理生理过程,调节高糖环境下胰岛β细胞的稳态.本文探讨了HIF-1α/PFKFB3信号通路介导的GK如何通过厌氧糖酵解、线粒体网络断裂、氧化应激和去分化诱导等过程导致T2DM中胰岛β细胞发生功能障碍.这一研究能为临床防治T2DM提供新的思路.
Islet β cells are the exclusive cellular source of insulin synthesis and secretion,playing a crucial role in regulating blood glucose homeostasis.The impairment of islet β cells due to sustained anaerobic glycolysis pressure represents a significant factor contributing to insulin deficiency or resistance in patients with type 2 diabetes mellitus(T2DM).Glucokinase(GK),serving as the principal rate-limiting step in glucose transport,exhibits close association with insulin secretion.Hypoxia-inducible factor 1α subunit(HIF-1α)and 6-phosphofructo-2-kinase(PFKFB3)act as pivotal regulatory factors within glycolysis.The HIF-1α/PFKFB3 signaling pathway participates in intricate pathophysiological processes involving islet β cell function and maintenance under high-glucose conditions.This review elucidates the mechanisms by which the HIF-1α/PFKFB3 signaling pathway mediates GK induction through anaerobic glycolysis,mitochondrial network adaptive fragmentation,oxidative stress,and dedifferentiation leading to pancreatic islet β cell dysfunction in T2DM,thereby offering novel insights for clinical prevention and treatment strategies targeting T2DM.
魏皓月;张茜;魏代浩;李欢;王瑞;黄延芹
山东中医药大学第一临床医学院,济南 250014北京中医药大学中医学院,北京 102488潍坊市中医院,潍坊 261000北京中医医院延庆医院,北京 102100山东中医药大学第一临床医学院,济南 250014山东中医药大学附属医院,济南 250011
临床医学
2型糖尿病葡萄糖激酶HIF-1α/PFKFB3信号通路线粒体去分化
type 2 diabetesglucokinaseHIF-1α/PFKFB3 signaling pathwaymitochondriadedifferentiation
《激光生物学报》 2024 (6)
512-522,11
国家自然科学基金项目(81974562)山东省泰山学者工程专项项目(tsqn202211354)山东省自然科学基金项目(ZR2024MH245)钱秋海全国名老中医药专家传承工作室建设项目(国中医药人教函[2022]75号).
评论